Browse
Submit Data
Databases
API
Help

Dataset Information

21 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)

ABSTRACT: To evaluate the clinical effectiveness of oral UFT/LV comparing 5-FU/l-LV as adjuvant therapy for stage III colorectal cancer.

DISEASE(S): Colorectal Neoplasms,Stage Iii Colorectal Cancer

PROVIDER: 2018788 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

| 2620921 | ecrin-mdr-crc

A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer

Project description:To compare the efficacy of tegafur/uracil (UFT) plus folinate calcium (leucovorin: LV) administered orally and UFT plus Krestin (PSK) administered orally enrolling patients with pTNM stage IIB or III colorectal cancer as subjects in a multicenter collaborative randomized open-label comparative controlled study and consequently to determine the usefulness of the above regimens as adjuvant therapy after surgery.

| 2033414 | ecrin-mdr-crc

Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancer

Project description:Interventions: UFT capsule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). UFT E-granule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). Primary outcome(s): treatment complete rate Study Design: Parallel Randomized

| 2626356 | ecrin-mdr-crc

Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer

Project description:The purpose of this study is to conduct a randomised controlled trial (RCT) comparing UFT/LV and UFT/LV + PSK in patients with histological stage IIIa/IIIb colorectal cancer who have undergone curative surgery without residual cancer using 3-year disease free survival (DFS) as the primary endpoint, and also to analyze the 3-year overall survival (OS), compliance, adverse events, quality of life (QOL) and relationship with tumor factors.

| 2041766 | ecrin-mdr-crc

Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group): Administration of 5 courses (6 months) of a schedule (consecutive administration method) in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group): Administration of 15 courses (18 months) of a schedule (5 days on, 2 days off: Saturday and Sunday) in which one course consists of 5 weeks of UFT (300 mg/m2/day) and LV (75 mg/day) for 5 consecutive days followed by 2 days off. Primary outcome(s): disease-free survival Study Design: Parallel Randomized

| 2609649 | ecrin-mdr-crc

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

Project description:A randomized controlled study is conducted on patients with histological stage III colorectal cancer assigned to postoperative adjuvant therapy of uracil-tegafur plus leucovorin (UFT+LV), UFT+LV / UFT, or UFT+LV+PSK / UFT+PSK. The usefulness of the three regimens was evaluated by comparing the disease-free survival rate, overall survival rate, incidence and severity of adverse event, and quality of life.

| 2020230 | ecrin-mdr-crc

A feasibility study of adjuvant therapy with UFT/LV plus oxaliplatin following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV until 1 year Primary outcome(s): Patients ratio with completion of adjuvant TEGAFOX therapy Study Design: Single arm Non-randomized

| 2618840 | ecrin-mdr-crc

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.

Project description:BackgroundThe Adjuvant Chemotherapy Trial of TS-1 for Colon Cancer (ACTS-CC) is a phase III trial designed to validate the non-inferiority of S-1 to UFT/leucovorin (LV) as postoperative adjuvant chemotherapy for stage III colon cancer. We report the results of a planned safety analysis.MethodsPatients aged 20-80 years with curatively resected stage III colon cancer were randomly assigned to receive UFT/LV (UFT, 300 mg m(-2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses) or S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses). Treatment status and safety were evaluated.ResultsOf 1535 enrolled patients, a total of 1504 (756 allocated to S-1 and 748 to UFT/LV) were analysed. The completion rate of protocol treatment was 77% in the S-1 group and 73% in the UFT/LV group. The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV. Stomatitis, anorexia, hyperpigmentation, and haematological toxicities were common in S-1, whereas increased alanine aminotransferase and aspartate aminotransferase were common in UFT/LV. The incidences of grade 3 AEs were 16% and 14%, respectively.ConclusionAlthough AE profiles differed between the groups, feasibility of the protocol treatment was good. Both S-1 and UFT/LV could be safely used as adjuvant chemotherapy.

| S-EPMC3314794 | biostudies-literature

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIV colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV Switch maintenance:5 course) UFT/LV p.o:4weeks on 1week off to be repeated every 5weeks Primary outcome(s): The complete of treatment,Safety Study Design: Single arm Non-randomized

| 2624724 | ecrin-mdr-crc

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIII colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV switch maintenance:5 course) UFT/LV p.o(4 weeks on,1week off ) to be repeated every 5 weeks. Primary outcome(s): The complete rate of treatment, Safety Study Design: Single arm Non-randomized

| 2624723 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data